IN8bioINAB
Market Cap: $14.4M
About: IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Employees: 39
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
2.41% less ownership
Funds ownership: 19.96% [Q1] → 17.55% (-2.41%) [Q2]
19% less funds holding
Funds holding: 32 [Q1] → 26 (-6) [Q2]
34% less capital invested
Capital invested by funds: $10.2M [Q1] → $6.77M (-$3.45M) [Q2]
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Research analyst outlook
We haven’t received any recent analyst ratings for INAB.